ReviewNature reviews. Neurology2022
Human cerebral organoids - a new tool for clinical neurology research.
Review in Nature reviews. Neurology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 176 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
176 citing papers in PubMed, 5 syntheses or guidelines pooled it.
- [Organoid-based strategies and challenges in tissue regeneration].Zhonghua shao shang yu chuang mian xiu fu za zhi · 2026Pooled it
- Mapping the Cerebral Organoid Landscape: A Systematic Review of Preclinical 3D Models in Neuroscience.Advanced healthcare materials · 2026Pooled it
- Pooled it
- Meta-analysis of single-cell RNA sequencing co-expression in human neural organoids reveals their high variability in recapitulating primary tissue.PLoS biology · 2024Pooled it
- Evaluation of Cell-Specific Alterations in Alzheimer's Disease and Relevance of In Vitro Models.Genes · 2023Pooled it
- Pathological Priming and Developmental Heterochrony as Organizing Concepts in Human iPSC Models of Autism Spectrum Disorder.Molecular neurobiology · 2026Review
- Bee-Derived Products in Neurodegenerative Diseases: Bioactive Constituents, Redox-Modulating Mechanisms, Evidence, and Translational Perspectives.Molecules (Basel, Switzerland) · 2026Review
- From Amyloid Exposure to Genetic Causality: Converging hiPSC-Based Models of Alzheimer's Disease.Cells · 2026Review
- A Fully Defined GelMA-Based Matrix Allows Fine Tuning of Tissue-Relevant Biomechanical and Biochemical Cues for Organoid Culture.Advanced healthcare materials · 2026Article
- Solute carrier membrane transporters: emerging targets in CNS disorders.Nature reviews. Drug discovery · 2026Review
- Human iPSC-Derived Brain Organoids: A Disease-Oriented Evaluation of Modeling Fidelity.The European journal of neuroscience · 2026Review
- A refined protocol for the large-scale production of high-quality cerebral organoids.Journal of neural transmission (Vienna, Austria : 1996) · 2026Article
- Organoid intelligence: a promising paradigm for autism spectrum disorder research.Molecular psychiatry · 2026Review
- OrgLine: A versatile pipeline for organoid morphometry using detector-guided prompts.Cell reports methods · 2026Article
- Label-free biochemical imaging and time point analysis of neural organoids via deep learning-enhanced Raman microspectroscopy.Science advances · 2026Article
- Engineering Neuronal Network Connectivity Through Precise and Scalable Electrical Modulation.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Organoids as brain tumour models: bridging the translational gap.Disease models & mechanisms · 2026Review
- Human amygdala-like telencephalic organoids model stress circuitry in assembloid systems.Cell stem cell · 2026Article
- Ethics and Regulation of Human Brain Organoid Research: Recommendations from the Asia Pacific Neuroethics Working Group.Asian bioethics review · 2026Article
- CRISPR screens in human neural organoids and assembloids.Nature protocols · 2026Review
116 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The current understanding of neurological diseases is derived mostly from direct analysis of patients and from animal models of disease. However, most patient studies do not capture the earliest stages of disease development and offer limited opportunities for experimental intervention, so rarely yield complete mechanistic insights. The use of animal models relies on evolutionary conservation of pathways involved in disease and is limited by an inability to recreate human-specific processes. In vitro models that are derived from human pluripotent stem cells cultured in 3D have emerged as a new model system that could bridge the gap between patient studies and animal models. In this Review, we summarize how such organoid models can complement classical approaches to accelerate neurological research. We describe our current understanding of neurodevelopment and how this process differs between humans and other animals, making human-derived models of disease essential. We discuss different methodologies for producing organoids and how organoids can be and have been used to model neurological disorders, including microcephaly, Zika virus infection, Alzheimer disease and other neurodegenerative disorders, and neurodevelopmental diseases, such as Timothy syndrome, Angelman syndrome and tuberous sclerosis. We also discuss the current limitations of organoid models and outline how organoids can be used to revolutionize research into the human brain and neurological diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.